Katkin Keith
Insider CIK 1314596 · RIGL Director · CBYL Director · EBS Director · SNDX Director · NVUS Director · UROV PEO;CEO/Urovant Sciences, Inc., Director · AVNR President and CEO, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| EBS Emergent BioSolutions Inc. | A Award deriv | 2026-04-30 | 2026-05-04 | 11,296 | — | $0 | 11,296 | SEC↗ |
| EBS Emergent BioSolutions Inc. | S Sale | 2026-04-30 | 2026-05-04 | 15,481 | $8.28 | $128.2K | 96,294 | SEC↗ |
| EBS Emergent BioSolutions Inc. | A Award | 2026-04-30 | 2026-05-04 | 25,344 | — | $0 | 111,775 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | A Award | 2026-02-04 | 2026-02-06 | 24,000 | — | $0 | 124,000 | SEC↗ |
| ELDN Eledon Pharmaceuticals, In | M Exercise deriv | 2026-01-10 | 2026-01-16 | 8,575 | — | $0 | 0 | SEC↗ |
| ELDN Eledon Pharmaceuticals, In | M Exercise | 2026-01-10 | 2026-01-16 | 8,575 | — | $0 | 8,575 | SEC↗ |
| EBS Emergent BioSolutions Inc. | S Sale | 2025-05-23 | 2025-05-28 | 7,844 | $6.30 | $49.4K | 86,431 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | P Buy | 2025-05-19 | 2025-05-19 | 10,000 | $9.11 | $91.1K | 100,000 | SEC↗ |
| EBS Emergent BioSolutions Inc. | A Award deriv | 2025-04-30 | 2025-05-02 | 15,824 | — | $0 | 41,572 | SEC↗ |
| EBS Emergent BioSolutions Inc. | A Award | 2025-04-30 | 2025-05-02 | 34,403 | — | $0 | 94,275 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | A Award | 2025-02-05 | 2025-02-07 | 25,000 | — | $0 | 90,000 | SEC↗ |
| ELDN Eledon Pharmaceuticals, In | A Award deriv | 2025-01-10 | 2025-01-13 | 77,175 | — | $0 | 77,175 | SEC↗ |
| ELDN Eledon Pharmaceuticals, In | A Award deriv | 2025-01-10 | 2025-01-13 | 8,575 | — | $0 | 8,575 | SEC↗ |
| EBS Emergent BioSolutions Inc. | A Award deriv | 2024-05-23 | 2024-05-28 | 25,748 | — | $0 | 25,748 | SEC↗ |
| EBS Emergent BioSolutions Inc. | A Award | 2024-05-23 | 2024-05-28 | 17,430 | — | $0 | 59,872 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | A Award | 2024-02-07 | 2024-02-09 | 17,000 | — | $0 | 65,000 | SEC↗ |
| EBS Emergent BioSolutions Inc. | A Award | 2023-05-25 | 2023-05-30 | 33,847 | — | $0 | 42,442 | SEC↗ |
| ELDN Eledon Pharmaceuticals, In | A Award deriv | 2023-05-01 | 2023-05-02 | 752,185 | — | $0 | 752,185 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | A Award | 2023-02-02 | 2023-02-03 | 16,000 | — | $0 | 48,000 | SEC↗ |
| ELDN Eledon Pharmaceuticals, In | A Award deriv | 2023-02-01 | 2023-02-02 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise deriv | 2022-10-06 | 2022-10-07 | 20,782 | — | $0 | 0 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise deriv | 2022-10-06 | 2022-10-07 | 9,117 | — | $0 | 0 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise | 2022-10-06 | 2022-10-07 | 20,782 | $7.88 | $163.8K | 52,782 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | S Sale | 2022-10-06 | 2022-10-07 | 9,117 | $25.90 | $236.1K | 32,000 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | S Sale | 2022-10-06 | 2022-10-07 | 20,782 | $25.90 | $538.3K | 32,000 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise | 2022-10-06 | 2022-10-07 | 9,117 | $8.93 | $81.4K | 41,117 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise deriv | 2022-10-04 | 2022-10-04 | 223 | — | $0 | 0 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise deriv | 2022-10-04 | 2022-10-04 | 137 | — | $0 | 0 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise | 2022-10-04 | 2022-10-04 | 137 | $7.88 | $1.1K | 32,137 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | S Sale | 2022-10-04 | 2022-10-04 | 137 | $25.00 | $3.4K | 32,000 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise | 2022-10-04 | 2022-10-04 | 223 | $8.93 | $2.0K | 32,223 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | S Sale | 2022-10-04 | 2022-10-04 | 223 | $25.00 | $5.6K | 32,000 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise deriv | 2022-10-03 | 2022-10-04 | 167 | — | $0 | 0 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise deriv | 2022-10-03 | 2022-10-04 | 13 | — | $0 | 0 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise | 2022-10-03 | 2022-10-04 | 167 | $7.88 | $1.3K | 32,167 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | S Sale | 2022-10-03 | 2022-10-04 | 167 | $25.00 | $4.2K | 32,000 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise | 2022-10-03 | 2022-10-04 | 13 | $8.93 | $116 | 32,013 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | S Sale | 2022-10-03 | 2022-10-04 | 13 | $25.00 | $325 | 32,000 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise deriv | 2022-09-30 | 2022-10-04 | 647 | — | $0 | 0 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise deriv | 2022-09-30 | 2022-10-04 | 2,914 | — | $0 | 0 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | S Sale | 2022-09-30 | 2022-10-04 | 2,914 | $25.07 | $73.1K | 32,000 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise | 2022-09-30 | 2022-10-04 | 647 | $8.93 | $5.8K | 32,647 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | S Sale | 2022-09-30 | 2022-10-04 | 647 | $25.07 | $16.2K | 32,000 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | M Exercise | 2022-09-30 | 2022-10-04 | 2,914 | $7.88 | $23.0K | 34,914 | SEC↗ |
| EBS Emergent BioSolutions Inc. | A Award | 2022-04-02 | 2022-04-05 | 8,595 | — | $0 | 8,595 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | A Award | 2022-02-02 | 2022-02-03 | 16,000 | — | $0 | 32,000 | SEC↗ |
| ELDN Eledon Pharmaceuticals, In | A Award deriv | 2022-02-01 | 2022-02-02 | 20,000 | — | $0 | 20,000 | SEC↗ |
| RIGL RIGEL PHARMACEUTICALS INC | A Award deriv | 2021-05-19 | 2021-05-21 | 30,000 | — | $0 | 30,000 | SEC↗ |
| RIGL RIGEL PHARMACEUTICALS INC | A Award | 2021-05-19 | 2021-05-21 | 25,000 | — | $0 | 25,000 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | A Award | 2021-02-03 | 2021-02-05 | 16,000 | — | $0 | 16,000 | SEC↗ |
| NVUS Novus Therapeutics, Inc. | A Award deriv | 2020-09-11 | 2020-09-15 | 5,907 | — | $0 | 5,907 | SEC↗ |
| RIGL RIGEL PHARMACEUTICALS INC | A Award deriv | 2020-05-15 | 2020-05-15 | 55,000 | — | $0 | 55,000 | SEC↗ |
| UROV Urovant Sciences Ltd. | M Exercise deriv | 2020-02-19 | 2020-02-21 | 180,000 | — | $0 | 701,254 | SEC↗ |
| UROV Urovant Sciences Ltd. | J Other | 2020-02-19 | 2020-02-21 | 75,212 | $13.08 | $983.8K | 199,680 | SEC↗ |
| UROV Urovant Sciences Ltd. | F Tax w/h | 2020-02-19 | 2020-02-21 | 104,788 | $13.08 | $1.37M | 274,892 | SEC↗ |
| UROV Urovant Sciences Ltd. | M Exercise | 2020-02-19 | 2020-02-21 | 180,000 | $3.86 | $694.8K | 379,680 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | A Award deriv | 2020-02-12 | 2020-02-14 | 24,000 | — | $0 | 24,000 | SEC↗ |
| UROV Urovant Sciences Ltd. | A Award | 2020-01-07 | 2020-01-09 | 199,680 | — | $0 | 199,680 | SEC↗ |
| UROV Urovant Sciences Ltd. | M Exercise deriv | 2019-12-09 | 2019-12-11 | 120,000 | — | $0 | 881,254 | SEC↗ |
| UROV Urovant Sciences Ltd. | M Exercise | 2019-12-09 | 2019-12-11 | 120,000 | $3.86 | $463.2K | 120,000 | SEC↗ |
| UROV Urovant Sciences Ltd. | S Sale | 2019-12-09 | 2019-12-11 | 120,000 | $12.78 | $1.53M | 0 | SEC↗ |
| NVUS Novus Therapeutics, Inc. | A Award deriv | 2019-07-11 | 2019-07-15 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | A Award deriv | 2019-06-10 | 2019-06-12 | 24,000 | — | $0 | 24,000 | SEC↗ |
| RIGL RIGEL PHARMACEUTICALS INC | A Award deriv | 2019-05-23 | 2019-05-24 | 55,000 | — | $0 | 55,000 | SEC↗ |
| UROV Urovant Sciences Ltd. | A Award deriv | 2019-01-06 | 2019-01-08 | 350,250 | — | $0 | 350,250 | SEC↗ |
| UROV Urovant Sciences Ltd. | A Award deriv | 2018-10-15 | 2018-10-17 | 99,967 | — | $0 | 99,967 | SEC↗ |
| UROV Urovant Sciences Ltd. | A Award deriv | 2018-10-01 | 2018-10-03 | 200,250 | — | $0 | 200,250 | SEC↗ |
| UROV Urovant Sciences Ltd. | A Award deriv | 2018-09-26 | 2018-09-28 | 39,815 | — | $0 | 39,815 | SEC↗ |
| NVUS Novus Therapeutics, Inc. | A Award deriv | 2018-06-13 | 2018-06-14 | 9,100 | — | $0 | 9,100 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | A Award deriv | 2018-05-23 | 2018-05-25 | 14,000 | — | $0 | 14,000 | SEC↗ |
| RIGL RIGEL PHARMACEUTICALS INC | A Award deriv | 2018-05-17 | 2018-05-18 | 40,000 | — | $0 | 40,000 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | A Award deriv | 2018-02-08 | 2018-02-12 | 10,000 | — | $0 | 10,000 | SEC↗ |
| NVUS Novus Therapeutics, Inc. | A Award deriv | 2017-06-30 | 2017-07-05 | 36,000 | — | $0 | 36,000 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | A Award deriv | 2017-05-17 | 2017-05-19 | 10,000 | — | $0 | 10,000 | SEC↗ |
| RIGL RIGEL PHARMACEUTICALS INC | A Award deriv | 2017-05-12 | 2017-05-12 | 40,000 | — | $0 | 40,000 | SEC↗ |
| SNDX Syndax Pharmaceuticals Inc | A Award deriv | 2017-03-29 | 2017-03-31 | 25,000 | — | $0 | 25,000 | SEC↗ |
| RIGL RIGEL PHARMACEUTICALS INC | A Award deriv | 2016-05-11 | 2016-05-12 | 40,000 | — | $0 | 40,000 | SEC↗ |
| CBYL Carbylan Therapeutics, Inc | A Award deriv | 2015-08-03 | 2015-08-05 | 29,000 | — | $0 | 29,000 | SEC↗ |
| RIGL RIGEL PHARMACEUTICALS INC | A Award deriv | 2015-06-29 | 2015-07-01 | 80,000 | — | $0 | 80,000 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2014-12-17 | 2014-12-18 | 62,520 | $16.93 | $1.06M | 914,249 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise deriv | 2014-12-15 | 2014-12-18 | 139,200 | — | $0 | 976,769 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise deriv | 2014-12-15 | 2014-12-18 | 55,960 | — | $0 | 976,769 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2014-12-15 | 2014-12-18 | 20,000 | $16.95 | $339.0K | 976,769 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise | 2014-12-15 | 2014-12-18 | 139,200 | $1.74 | $242.2K | 1,115,969 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise | 2014-12-15 | 2014-12-18 | 55,960 | $1.29 | $72.2K | 1,171,929 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2014-12-15 | 2014-12-18 | 195,160 | $16.95 | $3.31M | 976,769 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award | 2014-11-10 | 2014-11-12 | 140,611 | — | $0 | 996,769 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award | 2014-11-10 | 2014-11-12 | 220,563 | — | $0 | 856,158 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2014-10-24 | 2014-10-24 | 27,567 | $11.76 | $324.2K | 732,845 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2014-08-01 | 2014-08-01 | 9,670 | $5.26 | $50.9K | 760,412 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award | 2014-07-09 | 2014-07-10 | 20,000 | — | $0 | 770,082 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise deriv | 2014-05-28 | 2014-05-30 | 75,000 | — | $0 | 55,960 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise deriv | 2014-05-28 | 2014-05-30 | 317,212 | — | $0 | 0 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2014-05-28 | 2014-05-30 | 442,212 | $5.01 | $2.22M | 750,082 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | D To issuer deriv | 2014-05-20 | 2014-05-22 | 26,250 | — | $0 | 125,000 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award | 2014-02-12 | 2014-02-14 | 257,125 | — | $0 | 702,832 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award | 2014-02-12 | 2014-02-14 | 97,250 | — | $0 | 800,082 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2013-12-18 | 2013-12-20 | 29,515 | $2.67 | $78.8K | 445,707 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award deriv | 2013-12-13 | 2013-12-17 | 151,250 | — | $0 | 151,250 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2013-11-01 | 2013-11-05 | 4,385 | $4.14 | $18.2K | 475,222 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2013-08-02 | 2013-08-02 | 15,500 | $4.84 | $75.0K | 479,607 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise deriv | 2013-05-15 | 2013-05-17 | 159,638 | — | $0 | 53,212 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise deriv | 2013-05-15 | 2013-05-17 | 55,800 | — | $0 | 0 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise | 2013-05-15 | 2013-05-17 | 55,800 | $0.53 | $29.6K | 550,907 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2013-05-15 | 2013-05-17 | 35,000 | $3.26 | $114.1K | 495,107 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2013-05-15 | 2013-05-17 | 215,438 | $3.26 | $702.3K | 495,107 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise | 2013-05-15 | 2013-05-17 | 159,638 | $0.88 | $140.5K | 710,545 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award deriv | 2012-12-17 | 2012-12-19 | 225,000 | — | $0 | 225,000 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award | 2012-12-17 | 2012-12-19 | 73,125 | — | $0 | 530,107 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | A Award | 2012-12-17 | 2012-12-19 | 147,375 | — | $0 | 456,982 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2012-12-03 | 2012-12-05 | 18,250 | $2.55 | $46.5K | 119,482 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise deriv | 2012-06-25 | 2012-12-19 | 106,425 | — | $0 | 106,425 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise deriv | 2012-06-25 | 2012-12-19 | 83,700 | — | $0 | 83,700 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise | 2012-06-25 | 2012-12-19 | 106,425 | $0.88 | $93.7K | 327,857 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | M Exercise | 2012-06-25 | 2012-12-19 | 83,700 | $0.53 | $44.4K | 411,557 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | S Sale | 2012-06-25 | 2012-06-27 | 190,125 | $3.50 | $665.4K | 137,732 | SEC↗ |
| AVNR AVANIR PHARMACEUTICALS, IN | P Buy | 2012-03-06 | 2012-03-07 | 10,000 | $2.61 | $26.1K | 327,857 | SEC↗ |